At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Nemolizumabbiological
Likely dose
Nemolizumab 30 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics and Safety of Nemolizumab (CD14152) in Adolescent Subjects (12-17 Years) With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Nemolizumab for Atopic Dermatitis. Completed, enrolled 20 participants across 10 sites.
Detailed Summary
The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
First PostedApr 2019
Primary CompletionAug 2020
TodayJul 2026
First PostedApr 19, 2019
Enrollment StartApr 9, 2019
Primary CompletionAug 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.2 years ago
Interventions
Nemolizumabbiological
Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.